Blog

Questions 11 to 15 relate to the following case:  A practice pharmacist is carrying out routine medication reviews and discovers that a patient, Mrs. JN, has been inadvertently co-prescribed edoxaban and rivaroxaban following an unprovoked pulmonary embolism (PE) 2 weeks ago. The patient is contacted and confirms they have been taking both medications for 2 weeks; they state they feel well and haven’t experienced any signs of bleeding or bruising. The patient is advised to stop taking rivaroxaban and the pharmacist decides to investigate how the error has happened.  

Miss LR is found to have diabetic ketoacidosis (DKA) and is started on an intravenous insulin infusion.  Which statement is CORRECT? 

Baby A is prescribed propranolol oral solution for infantile haemangioma. Baby A weighs 3.9 kg and the starting dose is 1mg/kg daily in 3 divided doses.   Which product and label would be MOST APPROPRIATE to dispense for baby A? 

Following this, which would be the MOST APPROPRIATE course of action? 

Miss LR has been started on intravenous Tazocin® for pyelonephritis. After around 30 minutes, she starts to develop a severe rash, difficulty breathing and swelling of the face.   What type of adverse drug event is this? 

Following further investigation of her unprovoked PE, Mrs. JN is diagnosed with antiphospholipid syndrome.   Which anticoagulant would be MOST APPROPRIATE for Mrs. JN now? 

Which reversal agent is MOST APPROPRIATE for the management of morphine toxicity? 

How much aminophylline (rounded to the nearest 10 mg) would this patient receive in 24 hours? 

Which would be the MOST APPROPRIATE tool to investigate the incident? 

The nurse is educating a postoperative patient about the use of a patient-controlled analgesia (PCA) pump. Which statement by the patient indicates a need for further teaching?